Raymond James Trust N.A. Purchases 1,561 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Raymond James Trust N.A. increased its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 67.3% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,879 shares of the company’s stock after purchasing an additional 1,561 shares during the quarter. Raymond James Trust N.A.’s holdings in IDEXX Laboratories were worth $1,960,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Pacer Advisors Inc. raised its position in shares of IDEXX Laboratories by 14.4% during the 3rd quarter. Pacer Advisors Inc. now owns 13,742 shares of the company’s stock valued at $6,943,000 after acquiring an additional 1,729 shares during the last quarter. Massachusetts Financial Services Co. MA increased its holdings in IDEXX Laboratories by 4.0% in the third quarter. Massachusetts Financial Services Co. MA now owns 406,086 shares of the company’s stock valued at $205,163,000 after purchasing an additional 15,521 shares during the last quarter. Integrated Investment Consultants LLC lifted its stake in IDEXX Laboratories by 48.4% in the third quarter. Integrated Investment Consultants LLC now owns 650 shares of the company’s stock valued at $328,000 after buying an additional 212 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its stake in IDEXX Laboratories by 4.8% in the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 73,477 shares of the company’s stock valued at $37,122,000 after buying an additional 3,382 shares during the period. Finally, Citizens Financial Group Inc. RI boosted its holdings in IDEXX Laboratories by 26.4% during the third quarter. Citizens Financial Group Inc. RI now owns 853 shares of the company’s stock worth $431,000 after buying an additional 178 shares during the last quarter. 87.84% of the stock is owned by institutional investors.

IDEXX Laboratories Price Performance

Shares of NASDAQ IDXX opened at $417.24 on Friday. The company has a fifty day moving average price of $460.86 and a 200 day moving average price of $480.68. IDEXX Laboratories, Inc. has a 1-year low of $398.50 and a 1-year high of $583.39. The firm has a market cap of $34.17 billion, a PE ratio of 40.24, a PEG ratio of 3.65 and a beta of 1.36. The company has a current ratio of 1.42, a quick ratio of 1.03 and a debt-to-equity ratio of 0.32.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Thursday, October 31st. The company reported $2.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.69 by $0.11. The business had revenue of $975.50 million during the quarter, compared to the consensus estimate of $980.32 million. IDEXX Laboratories had a return on equity of 55.42% and a net margin of 22.53%. IDEXX Laboratories’s quarterly revenue was up 6.6% on a year-over-year basis. During the same period last year, the company earned $2.53 earnings per share. Research analysts predict that IDEXX Laboratories, Inc. will post 10.43 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. Barclays cut their price target on shares of IDEXX Laboratories from $570.00 to $481.00 and set an “overweight” rating on the stock in a research report on Monday, November 4th. Stifel Nicolaus reduced their price target on shares of IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating on the stock in a research report on Thursday, October 10th. Piper Sandler reissued a “neutral” rating and issued a $435.00 price target (down previously from $520.00) on shares of IDEXX Laboratories in a report on Monday, November 4th. Finally, JPMorgan Chase & Co. dropped their price objective on IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating on the stock in a research note on Friday, October 11th. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $552.38.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.